2020
DOI: 10.1158/1538-7445.am2020-785
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Abstract: Background: Clinical data characterizing the genomic markers of response to single agent CDK4 & 6 inhibitors are lacking. Abemaciclib is the only CDK4 & 6 inhibitor indicated as monotherapy for HR+, HER2- advanced breast cancer (ABC) following progression on endocrine therapy (ET) and prior chemotherapy (CT) in the metastatic setting. We explored the genomic alterations detected in baseline circulating tumor DNA (ctDNA) from patients (pts) treated with abemaciclib monotherapy in the nextMONARCH 1 study… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…While the combination of CDK4/6 inhibitors and AI is the most effective, ESR1 mutations can render the AI component ineffective. Furthermore, compared to palbociclib and ribociclib, abemaciclib is the only CDK4/6 inhibitor proven effective as monotherapy in later-line settings, and ESR1 mutations do not lead to resistance to its combination with AI [11,[67][68][69].…”
Section: Cdk4/6 Inhibitorsmentioning
confidence: 99%
“…While the combination of CDK4/6 inhibitors and AI is the most effective, ESR1 mutations can render the AI component ineffective. Furthermore, compared to palbociclib and ribociclib, abemaciclib is the only CDK4/6 inhibitor proven effective as monotherapy in later-line settings, and ESR1 mutations do not lead to resistance to its combination with AI [11,[67][68][69].…”
Section: Cdk4/6 Inhibitorsmentioning
confidence: 99%